KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Non-Current Assets (2023 - 2025)

Biocryst Pharmaceuticals' Non-Current Assets history spans 9 years, with the latest figure at $109.8 million for Q4 2025.

  • For Q4 2025, Non-Current Assets rose 60.42% year-over-year to $109.8 million; the TTM value through Dec 2025 reached $329.3 million, up 25.54%, while the annual FY2025 figure was $109.8 million, 60.42% up from the prior year.
  • Non-Current Assets reached $109.8 million in Q4 2025 per BCRX's latest filing, up from $90.7 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $109.8 million in Q4 2025 to a low of $18.8 million in Q2 2023.
  • Average Non-Current Assets over 3 years is $55.9 million, with a median of $61.4 million recorded in 2024.
  • Peak YoY movement for Non-Current Assets: surged 478.69% in 2024, then plummeted 46.1% in 2025.
  • A 3-year view of Non-Current Assets shows it stood at $21.0 million in 2023, then soared by 226.06% to $68.5 million in 2024, then surged by 60.42% to $109.8 million in 2025.
  • Per Business Quant, the three most recent readings for BCRX's Non-Current Assets are $109.8 million (Q4 2025), $90.7 million (Q3 2025), and $58.7 million (Q2 2025).